Skip to content

US · AMRX · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Amneal Pharmaceuticals, Inc. (AMRX) intrinsic value and stock valuation

$21.12as of 2026-11-21 · Mkt cap 5.89B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Amneal Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values AMRX with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from AMRX’s statements →

Amneal Pharmaceuticals, Inc. Graham Number

Graham Number: $0.31d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Bridgewater, NJ 08807 amneal.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$3.02B+8.7% 5y CAGRd
20142025
Net income
$72.1M-4.6% 5y CAGRd
20142025
Free cash flow
$269.9M-3.2% 5y CAGRd
20142025
Total equity
$5.96M-55.9% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$3.02B$2.79B$2.39B$2.21B$2.09B
Operating income$423.1M$249.3M$204.4M-$-94.93M$152.7M
Net income$72.1M-$-116.89M-$-83.99M-$-129.99M$10.6M
EPSd$221.9K-$-378.31K-$-476.84K-$-861.2K$70K
Operating cash flow$340M$295.1M$345.6M$65.1M$241.8M
Capital expenditure-$-70.06M-$-74.99M-$-69.19M-$-90.59M-$-47.73M
Free cash flow$269.9M$220.1M$276.4M-$-25.5M$194.1M
Total assets$3.68B$3.5B$3.47B$3.8B$3.94B
Total debt$2.74B$2.59B$2.75B$2.85B$2.88B
Net debt$2.43B$2.48B$2.66B$2.82B$2.63B
Total equity$5.96M-$-44.54M$61.3M$208.9M$367M
Cash and short-term investments$310.9M$112.4M$93.7M$27.8M$247.8M
Income statement
20252024202320222021
Revenue$3.02B$2.79B$2.39B$2.21B$2.09B
Cost of revenue$1.88B$1.77B$1.53B$1.42B$1.32B
Gross profit$1.14B$1.02B$863.9M$791.5M$769M
Research and development expenses$186.2M$190.7M$194.8M$208.7M$209.6M
Selling, general and administrative expenses$526.8M$476.4M$429.7M$399.7M$365.5M
Other expenses$0.00$104M$35.1M$278M$41.2M
Operating expenses$713M$771.1M$659.5M$886.4M$616.3M
Cost and expenses$2.6B$2.54B$2.19B$2.31B$1.94B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$241.1M$258.6M$210.6M$158.4M$136.3M
Depreciation and amortization$223.6M$236.2M$229.4M$240.2M$233.4M
Ebitda$603.9M$439.8M$500.8M$440.2M$401.1M
Operating income$423.1M$249.3M$204.4M-$-94.93M$152.7M
Total other income/expenses, net-$-283.88M-$-304.34M-$-244.64M-$-153.2M-$-121.35M
Income before tax$139.2M-$-55.01M-$-40.27M-$-248.13M$31.4M
Income tax expense$11.3M$18.9M$8.45M$6.66M$11.2M
Net income$72.1M-$-116.89M-$-83.99M-$-129.99M$10.6M
Weighted average shares outstanding$313.4M$309M$175M$150.9M$148.9M
Weighted average diluted shares outstanding$324.8M$309M$176.1M$150.9M$151.8M
Balance sheet
20252024202320222021
Cash and short-term investments$310.9M$112.4M$93.7M$27.8M$247.8M
Net receivables$939.9M$775.7M$645.7M$741.8M$694.7M
Inventory$606.3M$612.5M$581.4M$530.7M$489.4M
Total current assets$1.91B$1.59B$1.38B$1.41B$1.52B
Property, plant and equipment, net$550.3M$523.7M$550.1M$589.4M$639M
Goodwill and intangible assets$1.16B$1.33B$1.49B$1.69B$1.76B
Long-term investments$7.82M$35.9M$37.1M$85.6M$0.00
Total non-current assets$1.77B$1.91B$2.09B$2.39B$2.42B
Total assets$3.68B$3.5B$3.47B$3.8B$3.94B
Accounts payable$254.7M$259.8M$143.6M$166.8M$131.1M
Short-term debt$21.6M$340.3M$227.6M$104.6M$46M
Deferred revenue$0.00$0.00$398.4M$0.00$0.00
Total current liabilities$881.6M$1.13B$846.6M$752.8M$677.2M
Long-term debt$2.71B$2.25B$2.52B$2.74B$2.83B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.79B$2.42B$2.56B$2.84B$2.9B
Capital lease obligations$102.4M$107.1M$110M$123.5M$127.4M
Total liabilities$3.67B$3.55B$3.41B$3.59B$3.57B
Common stock$3.15M$3.1M$3.07M$3.04M$3.01M
Retained earnings-$-535M-$-607.06M-$-490.18M-$-406.18M-$-276.2M
Accumulated other comprehensive income (loss)-$-110.73M-$-65.51M-$-32.35M$9.94M-$-24.83M
Total equity$5.96M-$-44.54M$61.3M$208.9M$367M
Total investments$7.82M$37.8M$39.3M$87.4M$0.00
Total debt$2.74B$2.59B$2.75B$2.85B$2.88B
Net debt$2.43B$2.48B$2.66B$2.82B$2.63B
Cash flow statement
20252024202320222021
Net income$72.1M-$-73.88M-$-48.72M-$-254.79M$10.6M
Depreciation and amortization$223.6M$236.2M$229.4M$240.2M$233.4M
Stock-based compensation$32M$27.8M$26.8M$31.9M$0.00
Change in working capital-$-204.52M-$-4.07M-$-47.19M-$-59.95M-$-133.59M
Accounts receivable-$-120.57M-$-162.16M$125.8M-$-79.07M-$-16.31M
Inventory-$-87.03M-$-130.53M-$-126.18M-$-102.4M-$-49.02M
Accounts payable$21.3M$235.1M-$-94.45M$109.6M-$-43.93M
Net cash provided by operating activities$340M$295.1M$345.6M$65.1M$241.8M
Investments in property, plant and equipment-$-70.06M-$-60.34M-$-46.8M-$-48.8M-$-49.43M
Acquisitions, net$0.00$12M$0.00-$-84.71M-$-141.54M
Net cash used for investing activities-$-112.26M-$-63M-$-69.19M-$-174.31M-$-194.18M
Common stock issued$1.96M$0.00$0.00$0.00$850K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-31.53M-$-211.79M-$-212.57M-$-106.62M-$-138.12M
Net change in cash$194.5M$19.3M$63.9M-$-221.51M-$-90.38M
Cash at end of period$312.9M$118.4M$99.1M$35.2M$256.7M
Operating cash flow$340M$295.1M$345.6M$65.1M$241.8M
Capital expenditure-$-70.06M-$-74.99M-$-69.19M-$-90.59M-$-47.73M
Free cash flow$269.9M$220.1M$276.4M-$-25.5M$194.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Amneal Pharmaceuticals, Inc.

        Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

        CEO
        Chirag K. Patel
        Employees
        8.5K
        Beta
        1.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Amneal Pharmaceuticals, Inc. (AMRX)?

        Amneal Pharmaceuticals, Inc. (AMRX) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AMRX undervalued?

        AMRX trades at a price of $21.12 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.